SCHEMBL13628275

SCHEMBL13628275

CC(=O)OC(C(=O)Nc1ccc2c(c1)N(Cc1cc(F)cc3c1OCOC3)C(=O)/C2=N/O)c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MAPT P10636 2/20 0.33
TAS2R8 Q9NYW2 1/20 0.33
MAPK8 P45983 1/20 0.33
CXCR5 P32302 1/20 0.33
MEN1 O00255 1/20 0.33
HTR1E P28566 1/20 0.33
KMT2A Q03164 1/20 0.33
S1PR3 Q99500 1/20 0.33
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 1/20 0.33
GALR3 O60755 1/20 0.32
NR2F2 P24468 1/20 0.32
TSHR P16473 3/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2C9 P11712 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628279 0.89 KCNQ2 (0.39) NPC1POLBRAB9ANPSR1MAPT
SCHEMBL13628208 0.88 KDM4E (0.38) NPC1POLBRAB9ANPSR1MAPK8
SCHEMBL13628152 0.86 MAPK8 (0.39) NPC1POLBRAB9ANPSR1MAPK8
SCHEMBL13628195 0.84 RPS6KA2 (0.40) NPC1POLBRAB9ANPSR1MAPK8
SCHEMBL13628308 0.84 MAPK8 (0.39) NPC1POLBRAB9ANPSR1MAPT
SCHEMBL13628155 0.83 KDM4E (0.38) NPC1POLBRAB9ANPSR1MAPT
SCHEMBL13628309 0.83 LMNA (0.38) NPC1POLBRAB9ANPSR1MAPT
SCHEMBL13628206 0.83 TDP1 (0.38) NPC1POLBRAB9ANPSR1MAPT
SCHEMBL13628314 0.82 ALDH1A1 (0.37) NPC1POLBRAB9ANPSR1MAPT
SCHEMBL13628163 0.82 KDM4E (0.43) NPC1POLBRAB9ANPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 NPC1 1715/4885POLB 2623/4885RAB9A 3486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.